You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBupranolol
Accession NumberDB08808
TypeSmall Molecule
GroupsApproved
DescriptionBupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to "propranolol":http://www.drugbank.ca/drugs/DB00571.
Structure
Thumb
Synonyms
Bupranol
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetadrenolDesma
OphtoreninWinzer (Germany)
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bupranolol hydrochloride
15148-80-8
Thumb
  • InChI Key: WJUUZHQWGKSLIJ-UHFFFAOYSA-N
  • Monoisotopic Mass: 307.1105844
  • Average Mass: 308.24
DBSALT000905
Categories
UNII858YGI5PIT
CAS number14556-46-8
WeightAverage: 271.783
Monoisotopic: 271.13390666
Chemical FormulaC14H22ClNO2
InChI KeyInChIKey=HQIRNZOQPUAHHV-UHFFFAOYSA-N
InChI
InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3
IUPAC Name
1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
SMILES
CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationUsed to manage hypertension and tachycardia. Also used to treat glaucoma.
PharmacodynamicsBupranolol is a competitive, nonselective beta-blocker similar to propanolol without intrinsic sympathomimetic activity.
Mechanism of actionBupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.
Related Articles
AbsorptionQuickly and completely absorbed from the gut with less than 10% oral bioavailability.
Volume of distributionNot Available
Protein binding76%
Metabolism

Over 90% undergo first-pass metabolism. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid, of which 88% are eliminated renally within 24 hours.

SubstrateEnzymesProduct
Bupranolol
Not Available
carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acidDetails
Route of eliminationNot Available
Half life2-4 hours
ClearanceNot Available
ToxicitySymptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bupranolol Action PathwayDrug actionSMP00670
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9784
Blood Brain Barrier-0.7572
Caco-2 permeable+0.5576
P-glycoprotein substrateSubstrate0.6384
P-glycoprotein inhibitor INon-inhibitor0.6857
P-glycoprotein inhibitor IINon-inhibitor0.8993
Renal organic cation transporterNon-inhibitor0.8713
CYP450 2C9 substrateNon-substrate0.8011
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6373
CYP450 1A2 substrateInhibitor0.5416
CYP450 2C9 inhibitorNon-inhibitor0.8165
CYP450 2D6 inhibitorInhibitor0.6045
CYP450 2C19 inhibitorNon-inhibitor0.7218
CYP450 3A4 inhibitorNon-inhibitor0.8424
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5726
Ames testNon AMES toxic0.9025
CarcinogenicityNon-carcinogens0.8249
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4441 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Non-inhibitor0.6443
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP3.14ALOGPS
logP2.99ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity74.86 m3·mol-1ChemAxon
Polarizability30.35 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Kunz, W., Jacobi, H., Koch, C. and Geus, R.J.; U.S. Patent 3,309,406; March 14, 1967.

General ReferencesNot Available
External Links
ATC CodesC07AA19
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bupranolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bupranolol.
AcebutololAcebutolol may increase the hypotensive activities of Bupranolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Bupranolol.
AcepromazineAcepromazine may increase the hypotensive activities of Bupranolol.
AcetohexamideBupranolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Acetylcholine.
AcetyldigitoxinBupranolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bupranolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Bupranolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Bupranolol.
AlfuzosinBupranolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Bupranolol.
AliskirenBupranolol may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Bupranolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Bupranolol.
AmbrisentanBupranolol may increase the hypotensive activities of Ambrisentan.
AmifostineBupranolol may increase the hypotensive activities of Amifostine.
AminophyllineBupranolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Bupranolol.
AmlodipineAmlodipine may increase the hypotensive activities of Bupranolol.
AmobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Amobarbital.
AmodiaquineThe metabolism of Bupranolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Bupranolol can be increased when it is combined with Amoxapine.
AntipyrineAntipyrine may decrease the antihypertensive activities of Bupranolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
ApraclonidineApraclonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
ApremilastApremilast may decrease the antihypertensive activities of Bupranolol.
ArbutamineBupranolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Arecoline.
ArformoterolBupranolol may decrease the bronchodilatory activities of Arformoterol.
AtenololAtenolol may increase the hypotensive activities of Bupranolol.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bupranolol.
AzelastineAzelastine may decrease the antihypertensive activities of Bupranolol.
BalsalazideBalsalazide may decrease the antihypertensive activities of Bupranolol.
BambuterolBupranolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Barbital.
BenazeprilBenazepril may increase the hypotensive activities of Bupranolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bupranolol.
BenmoxinBenmoxin may increase the hypotensive activities of Bupranolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bupranolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BepridilBepridil may increase the hypotensive activities of Bupranolol.
BetaxololBetaxolol may increase the hypotensive activities of Bupranolol.
BethanecholThe risk or severity of adverse effects can be increased when Bupranolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Bupranolol.
BimatoprostBimatoprost may increase the hypotensive activities of Bupranolol.
BisoprololBisoprolol may increase the hypotensive activities of Bupranolol.
BosentanBosentan may increase the hypotensive activities of Bupranolol.
BretyliumBretylium may increase the hypotensive activities of Bupranolol.
BrimonidineBupranolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Bupranolol.
BromfenacBromfenac may decrease the antihypertensive activities of Bupranolol.
BromocriptineBupranolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bupranolol.
CabergolineBupranolol may increase the vasoconstricting activities of Cabergoline.
CandesartanCandesartan may increase the hypotensive activities of Bupranolol.
CandoxatrilCandoxatril may increase the hypotensive activities of Bupranolol.
CaptoprilCaptopril may increase the hypotensive activities of Bupranolol.
CarbacholThe risk or severity of adverse effects can be increased when Bupranolol is combined with Carbachol.
CaroxazoneCaroxazone may increase the hypotensive activities of Bupranolol.
CarprofenCarprofen may decrease the antihypertensive activities of Bupranolol.
CarteololCarteolol may increase the hypotensive activities of Bupranolol.
CarvedilolCarvedilol may increase the hypotensive activities of Bupranolol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Bupranolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Bupranolol.
CeliprololCeliprolol may increase the hypotensive activities of Bupranolol.
CeliprololBupranolol may decrease the bronchodilatory activities of Celiprolol.
CevimelineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Bupranolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bupranolol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bupranolol.
ChlorpropamideBupranolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bupranolol.
CilazaprilCilazapril may increase the hypotensive activities of Bupranolol.
ClenbuterolBupranolol may decrease the bronchodilatory activities of Clenbuterol.
ClomipramineThe serum concentration of Bupranolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Bupranolol.
ClonixinClonixin may decrease the antihypertensive activities of Bupranolol.
CoumaphosCoumaphos may increase the bradycardic activities of Bupranolol.
CryptenamineCryptenamine may increase the hypotensive activities of Bupranolol.
CyclothiazideCyclothiazide may increase the hypotensive activities of Bupranolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bupranolol.
DapoxetineThe serum concentration of Bupranolol can be increased when it is combined with Dapoxetine.
DebrisoquinDebrisoquin may increase the hypotensive activities of Bupranolol.
DecamethoniumDecamethonium may increase the bradycardic activities of Bupranolol.
DemecariumDemecarium may increase the bradycardic activities of Bupranolol.
DeserpidineBupranolol may increase the hypotensive activities of Deserpidine.
DeslanosideBupranolol may increase the bradycardic activities of Deslanoside.
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
DiazoxideDiazoxide may increase the hypotensive activities of Bupranolol.
DichlorvosDichlorvos may increase the bradycardic activities of Bupranolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Bupranolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Bupranolol.
DigitoxinBupranolol may increase the bradycardic activities of Digitoxin.
DigoxinBupranolol may increase the bradycardic activities of Digoxin.
DihydroergotamineBupranolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
DiltiazemDiltiazem may increase the hypotensive activities of Bupranolol.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bupranolol.
DipivefrinBupranolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Bupranolol.
DisopyramideDisopyramide may increase the bradycardic activities of Bupranolol.
DobutamineBupranolol may decrease the bronchodilatory activities of Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Bupranolol.
DorzolamideDorzolamide may increase the hypotensive activities of Bupranolol.
DoxazosinDoxazosin may increase the hypotensive activities of Bupranolol.
DronedaroneDronedarone may increase the bradycardic activities of Bupranolol.
DroxicamDroxicam may decrease the antihypertensive activities of Bupranolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bupranolol.
DroxidopaBupranolol may decrease the bronchodilatory activities of Droxidopa.
DyphyllineBupranolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Bupranolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Bupranolol.
EfonidipineBupranolol may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Bupranolol.
EnalaprilatBupranolol may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bupranolol.
EphedraBupranolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Bupranolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
EpinephrineBupranolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Bupranolol.
EpoprostenolEpoprostenol may increase the hypotensive activities of Bupranolol.
EprosartanEprosartan may increase the hypotensive activities of Bupranolol.
Ergoloid mesylateBupranolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineBupranolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineBupranolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Bupranolol.
EtodolacEtodolac may decrease the antihypertensive activities of Bupranolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Bupranolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bupranolol.
EtoperidoneThe serum concentration of Bupranolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bupranolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bupranolol.
exisulindexisulind may decrease the antihypertensive activities of Bupranolol.
FelodipineFelodipine may increase the hypotensive activities of Bupranolol.
FenbufenFenbufen may decrease the antihypertensive activities of Bupranolol.
FenfluramineThe serum concentration of Bupranolol can be increased when it is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Bupranolol.
FenoprofenFenoprofen may decrease the antihypertensive activities of Bupranolol.
FenoterolBupranolol may decrease the bronchodilatory activities of Fenoterol.
FenthionFenthion may increase the bradycardic activities of Bupranolol.
FingolimodBupranolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bupranolol.
FlunixinFlunixin may decrease the antihypertensive activities of Bupranolol.
FluoxetineThe serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Bupranolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bupranolol.
FormoterolBupranolol may decrease the bronchodilatory activities of Formoterol.
FosinoprilFosinopril may increase the hypotensive activities of Bupranolol.
FurazolidoneFurazolidone may increase the hypotensive activities of Bupranolol.
GalantamineGalantamine may increase the bradycardic activities of Bupranolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bupranolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bupranolol.
GlibornurideBupranolol may increase the hypoglycemic activities of Glibornuride.
GliclazideBupranolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideBupranolol may increase the hypoglycemic activities of Glimepiride.
GlipizideBupranolol may increase the hypoglycemic activities of Glipizide.
GliquidoneBupranolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideBupranolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideBupranolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Bupranolol is combined with GTS-21.
GuanabenzGuanabenz may increase the hypotensive activities of Bupranolol.
GuanadrelGuanadrel may increase the hypotensive activities of Bupranolol.
GuanethidineGuanethidine may increase the hypotensive activities of Bupranolol.
GuanfacineGuanfacine may increase the hypotensive activities of Bupranolol.
HexamethoniumBupranolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Hexobarbital.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Bupranolol.
Huperzine AHuperzine A may increase the bradycardic activities of Bupranolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Bupranolol.
HydralazineHydralazine may increase the hypotensive activities of Bupranolol.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bupranolol.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bupranolol.
HydroxychloroquineThe metabolism of Bupranolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Bupranolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Bupranolol.
IcatibantIcatibant may decrease the antihypertensive activities of Bupranolol.
IloprostIloprost may increase the hypotensive activities of Bupranolol.
IndacaterolBupranolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Bupranolol can be increased when it is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Bupranolol.
IndenololBupranolol may increase the hypotensive activities of Indenolol.
IndomethacinIndomethacin may decrease the antihypertensive activities of Bupranolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Bupranolol.
IndoraminBupranolol may increase the hypotensive activities of Indoramin.
Insulin PorkBupranolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Bupranolol.
IproniazidIproniazid may increase the hypotensive activities of Bupranolol.
IrbesartanIrbesartan may increase the hypotensive activities of Bupranolol.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bupranolol.
IsoetarineBupranolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Bupranolol.
IsoprenalineBupranolol may decrease the bronchodilatory activities of Isoprenaline.
IsoxicamIsoxicam may decrease the antihypertensive activities of Bupranolol.
IsradipineIsradipine may increase the hypotensive activities of Bupranolol.
KebuzoneKebuzone may decrease the antihypertensive activities of Bupranolol.
KetoprofenKetoprofen may decrease the antihypertensive activities of Bupranolol.
KetorolacKetorolac may decrease the antihypertensive activities of Bupranolol.
LabetalolLabetalol may increase the hypotensive activities of Bupranolol.
LacidipineBupranolol may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Bupranolol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Bupranolol.
LercanidipineLercanidipine may increase the hypotensive activities of Bupranolol.
LevomilnacipranThe serum concentration of Bupranolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bupranolol.
LisinoprilLisinopril may increase the hypotensive activities of Bupranolol.
LobelineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Lobeline.
LofexidineLofexidine may increase the hypotensive activities of Bupranolol.
LornoxicamLornoxicam may decrease the antihypertensive activities of Bupranolol.
LosartanLosartan may increase the hypotensive activities of Bupranolol.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bupranolol.
Lu AA21004The serum concentration of Bupranolol can be increased when it is combined with Lu AA21004.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bupranolol.
MacitentanBupranolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bupranolol.
MalathionMalathion may increase the bradycardic activities of Bupranolol.
ManidipineBupranolol may increase the hypotensive activities of Manidipine.
MasoprocolMasoprocol may decrease the antihypertensive activities of Bupranolol.
MebanazineMebanazine may increase the hypotensive activities of Bupranolol.
MecamylamineMecamylamine may increase the hypotensive activities of Bupranolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bupranolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bupranolol.
MefloquineMefloquine may increase the bradycardic activities of Bupranolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Bupranolol.
MemantineMemantine may increase the bradycardic activities of Bupranolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bupranolol.
MesalazineMesalazine may decrease the antihypertensive activities of Bupranolol.
MesoridazineMesoridazine may increase the hypotensive activities of Bupranolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Bupranolol.
MethacholineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Methacholine.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
MethohexitalThe serum concentration of Bupranolol can be decreased when it is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bupranolol.
MethyldopaMethyldopa may increase the hypotensive activities of Bupranolol.
Methylene blueMethylene blue may increase the hypotensive activities of Bupranolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bupranolol.
MethylphenobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Methylphenobarbital.
MetipranololMetipranolol may increase the hypotensive activities of Bupranolol.
MetolazoneMetolazone may increase the hypotensive activities of Bupranolol.
MetoprololMetoprolol may increase the hypotensive activities of Bupranolol.
MibefradilMibefradil may increase the hypotensive activities of Bupranolol.
MidodrineBupranolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Bupranolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Bupranolol.
MinoxidilMinoxidil may increase the hypotensive activities of Bupranolol.
MoclobemideMoclobemide may increase the hypotensive activities of Bupranolol.
MoexiprilMoexipril may increase the hypotensive activities of Bupranolol.
MolsidomineMolsidomine may increase the hypotensive activities of Bupranolol.
MoricizineMoricizine may increase the hypotensive activities of Bupranolol.
MoxonidineBupranolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bupranolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bupranolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Bupranolol.
NadololNadolol may increase the hypotensive activities of Bupranolol.
NaftifineNaftifine may decrease the antihypertensive activities of Bupranolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.
NaproxenNaproxen may decrease the antihypertensive activities of Bupranolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Bupranolol.
NebivololNebivolol may increase the hypotensive activities of Bupranolol.
NeostigmineNeostigmine may increase the bradycardic activities of Bupranolol.
NepafenacNepafenac may decrease the antihypertensive activities of Bupranolol.
NialamideNialamide may increase the hypotensive activities of Bupranolol.
NicardipineNicardipine may increase the hypotensive activities of Bupranolol.
NicorandilBupranolol may increase the hypotensive activities of Nicorandil.
NicotineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Bupranolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Bupranolol.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bupranolol.
NiguldipineBupranolol may increase the hypotensive activities of Niguldipine.
NilvadipineNilvadipine may increase the hypotensive activities of Bupranolol.
NimesulideNimesulide may decrease the antihypertensive activities of Bupranolol.
NimodipineNimodipine may increase the hypotensive activities of Bupranolol.
NisoldipineNisoldipine may increase the hypotensive activities of Bupranolol.
NitrendipineNitrendipine may increase the hypotensive activities of Bupranolol.
NitroprussideNitroprusside may increase the hypotensive activities of Bupranolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
NorepinephrineBupranolol may decrease the bronchodilatory activities of Norepinephrine.
ObinutuzumabBupranolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Bupranolol.
OlanzapineThe serum concentration of Bupranolol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Bupranolol.
OlodaterolBupranolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Bupranolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Bupranolol.
OmapatrilatOmapatrilat may increase the hypotensive activities of Bupranolol.
OrciprenalineBupranolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Bupranolol.
OuabainBupranolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Bupranolol.
OxprenololOxprenolol may increase the hypotensive activities of Bupranolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bupranolol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.
ParecoxibParecoxib may decrease the antihypertensive activities of Bupranolol.
PargylinePargyline may increase the hypotensive activities of Bupranolol.
ParoxetineThe serum concentration of Bupranolol can be increased when it is combined with Paroxetine.
PenbutololPenbutolol may increase the hypotensive activities of Bupranolol.
PentobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Pentobarbital.
PentoliniumPentolinium may increase the hypotensive activities of Bupranolol.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bupranolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bupranolol.
PerindoprilPerindopril may increase the hypotensive activities of Bupranolol.
PerphenazinePerphenazine may increase the hypotensive activities of Bupranolol.
PhenelzinePhenelzine may increase the hypotensive activities of Bupranolol.
PheniprazinePheniprazine may increase the hypotensive activities of Bupranolol.
PhenobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Phenobarbital.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Bupranolol.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bupranolol.
PhentolaminePhentolamine may increase the hypotensive activities of Bupranolol.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bupranolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
PhenylpropanolamineBupranolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Bupranolol.
PilocarpineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bupranolol.
PinacidilPinacidil may increase the hypotensive activities of Bupranolol.
PindololPindolol may increase the hypotensive activities of Bupranolol.
PirbuterolBupranolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Bupranolol.
PirlindolePirlindole may increase the hypotensive activities of Bupranolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Bupranolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Bupranolol.
PolythiazidePolythiazide may increase the hypotensive activities of Bupranolol.
PrazosinPrazosin may increase the hypotensive activities of Bupranolol.
PrimaquineThe metabolism of Bupranolol can be decreased when combined with Primaquine.
PrimidoneThe serum concentration of Bupranolol can be decreased when it is combined with Primidone.
ProcaterolBupranolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bupranolol.
PromazinePromazine may increase the hypotensive activities of Bupranolol.
PromethazinePromethazine may increase the hypotensive activities of Bupranolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Bupranolol.
PropafenoneThe serum concentration of Bupranolol can be increased when it is combined with Propafenone.
PropranololPropranolol may increase the hypotensive activities of Bupranolol.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
PTC299PTC299 may decrease the antihypertensive activities of Bupranolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Bupranolol.
QuinaprilQuinapril may increase the hypotensive activities of Bupranolol.
QuinineQuinine may increase the hypotensive activities of Bupranolol.
RamiprilRamipril may increase the hypotensive activities of Bupranolol.
RasagilineRasagiline may increase the hypotensive activities of Bupranolol.
RegorafenibRegorafenib may increase the bradycardic activities of Bupranolol.
RemikirenRemikiren may increase the hypotensive activities of Bupranolol.
RescinnamineBupranolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Bupranolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Bupranolol.
RiociguatBupranolol may increase the hypotensive activities of Riociguat.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.
RitodrineBupranolol may decrease the bronchodilatory activities of Ritodrine.
RituximabBupranolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Bupranolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Bupranolol.
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bupranolol.
SafrazineSafrazine may increase the hypotensive activities of Bupranolol.
SalbutamolBupranolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Bupranolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bupranolol.
SalmeterolBupranolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Bupranolol.
SaprisartanSaprisartan may increase the hypotensive activities of Bupranolol.
SecobarbitalThe serum concentration of Bupranolol can be decreased when it is combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Bupranolol.
SelexipagBupranolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Bupranolol.
SertralineThe serum concentration of Bupranolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Bupranolol.
SilodosinBupranolol may increase the orthostatic hypotensive activities of Silodosin.
SitaxentanBupranolol may increase the hypotensive activities of Sitaxentan.
SpiraprilSpirapril may increase the hypotensive activities of Bupranolol.
SRT501SRT501 may decrease the antihypertensive activities of Bupranolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bupranolol.
SulindacSulindac may decrease the antihypertensive activities of Bupranolol.
SuprofenSuprofen may decrease the antihypertensive activities of Bupranolol.
TacrineTacrine may increase the bradycardic activities of Bupranolol.
TadalafilTadalafil may increase the antihypertensive activities of Bupranolol.
TamsulosinBupranolol may increase the orthostatic hypotensive activities of Tamsulosin.
TelmisartanTelmisartan may increase the hypotensive activities of Bupranolol.
TemocaprilBupranolol may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Bupranolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Bupranolol.
TerazosinBupranolol may increase the orthostatic hypotensive activities of Terazosin.
TerbutalineBupranolol may decrease the bronchodilatory activities of Terbutaline.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bupranolol.
TerlipressinTerlipressin may increase the hypotensive activities of Bupranolol.
TheophyllineBupranolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThe serum concentration of Bupranolol can be decreased when it is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bupranolol.
ThiopentalThe serum concentration of Bupranolol can be decreased when it is combined with Thiopental.
ThioridazineThioridazine may increase the hypotensive activities of Bupranolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bupranolol.
TiboloneBupranolol may increase the hypotensive activities of Tibolone.
TicrynafenTicrynafen may increase the hypotensive activities of Bupranolol.
TimololTimolol may increase the hypotensive activities of Bupranolol.
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
TolazamideBupranolol may increase the hypoglycemic activities of Tolazamide.
TolazolineTolazoline may increase the hypotensive activities of Bupranolol.
TolbutamideBupranolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bupranolol.
TolmetinTolmetin may decrease the antihypertensive activities of Bupranolol.
ToloxatoneToloxatone may increase the hypotensive activities of Bupranolol.
TorasemideTorasemide may increase the hypotensive activities of Bupranolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Bupranolol.
TranilastTranilast may decrease the antihypertensive activities of Bupranolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bupranolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Bupranolol.
TravoprostTravoprost may increase the hypotensive activities of Bupranolol.
TrazodoneThe serum concentration of Bupranolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Bupranolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Bupranolol.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bupranolol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bupranolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Bupranolol.
TrimazosinBupranolol may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Bupranolol.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Bupranolol.
TubocurarineTubocurarine may increase the bradycardic activities of Bupranolol.
UdenafilUdenafil may increase the antihypertensive activities of Bupranolol.
UnoprostoneUnoprostone may increase the hypotensive activities of Bupranolol.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bupranolol.
ValsartanValsartan may increase the hypotensive activities of Bupranolol.
VardenafilVardenafil may increase the antihypertensive activities of Bupranolol.
VareniclineThe risk or severity of adverse effects can be increased when Bupranolol is combined with Varenicline.
VilanterolBupranolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Bupranolol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Bupranolol can be increased when it is combined with Vortioxetine.
XylometazolineXylometazoline may increase the hypotensive activities of Bupranolol.
YohimbineYohimbine may decrease the antihypertensive activities of Bupranolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bupranolol.
ZileutonZileuton may decrease the antihypertensive activities of Bupranolol.
ZimelidineThe serum concentration of Bupranolol can be increased when it is combined with Zimelidine.
ZomepiracZomepirac may decrease the antihypertensive activities of Bupranolol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Zelaszczyk D, Kozlowska H, Baranowska U, Baranowska M, Reutelsterz A, Kiec-Kononowicz K, Malinowska B, Schlicker E: Four close bupranolol analogues are antagonists at the low-affinity state of beta1-adrenoceptors. J Physiol Pharmacol. 2009 Mar;60(1):51-60. [PubMed:19439807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003 May;305(2):653-9. Epub 2003 Jan 24. [PubMed:12606631 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003 May;305(2):653-9. Epub 2003 Jan 24. [PubMed:12606631 ]
  2. Matsushita M, Horinouchi T, Tanaka Y, Tsuru H, Koike K: Characterization of beta 3-adrenoceptor-mediated relaxation in rat abdominal aorta smooth muscle. Eur J Pharmacol. 2003 Dec 15;482(1-3):235-44. [PubMed:14660028 ]
Comments
comments powered by Disqus
Drug created on October 20, 2010 15:45 / Updated on August 17, 2016 12:24